- Home
- DRCT vs VYNE Comparison
DRCT vs VYNE Comparison
Compare DRCT & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- VYNE
- Stock Information
- Founded
- DRCT 2018
- VYNE 2003
- Country
- DRCT United States
- VYNE United States
- Employees
- DRCT N/A
- VYNE N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- VYNE Health Care
- Exchange
- DRCT Nasdaq
- VYNE Nasdaq
- Market Cap
- DRCT 38.7M
- VYNE 41.9M
- IPO Year
- DRCT 2022
- VYNE 2018
- Fundamental
- Price
- DRCT $1.96
- VYNE $2.92
- Analyst Decision
- DRCT Strong Buy
- VYNE Strong Buy
- Analyst Count
- DRCT 3
- VYNE 1
- Target Price
- DRCT $21.00
- VYNE $5.75
- AVG Volume (30 Days)
- DRCT 91.1K
- VYNE 143.8K
- Earning Date
- DRCT 11-12-2024
- VYNE 11-07-2024
- Dividend Yield
- DRCT N/A
- VYNE N/A
- EPS Growth
- DRCT N/A
- VYNE N/A
- EPS
- DRCT N/A
- VYNE N/A
- Revenue
- DRCT $94,216,000.00
- VYNE $493,000.00
- Revenue This Year
- DRCT $17.00
- VYNE $32.31
- Revenue Next Year
- DRCT $13.27
- VYNE N/A
- P/E Ratio
- DRCT N/A
- VYNE N/A
- Revenue Growth
- DRCT N/A
- VYNE 39.27
- 52 Week Low
- DRCT $1.85
- VYNE $1.57
- 52 Week High
- DRCT $35.88
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- DRCT 37.42
- VYNE 62.09
- Support Level
- DRCT $1.85
- VYNE $2.86
- Resistance Level
- DRCT $2.67
- VYNE $3.05
- Average True Range (ATR)
- DRCT 0.24
- VYNE 0.22
- MACD
- DRCT -0.08
- VYNE -0.02
- Stochastic Oscillator
- DRCT 13.33
- VYNE 45.45
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.